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 Drug metabolizing enzymes play a key role in metabolism, elimination and 
detoxification of xenobiotics exposed to the body and protect the organism from potentially 
harmful effect of xenobiotics as well as certain endobiotics. Phase I and II drug metabolizing 
enzymes and drug transporters are expressed in most tissues in basal level or may be induced 
after exposure to xenobiotics. Affecting of expression or activity of drug metabolizing 
enzymes and drug transporters may result in unpredictable tissue and systemic drug 
distribution, to side effects or therapy failure. Up-regulation of drug metabolizing enzymes 
and drug transporters mediates mainly orphan nuclear receptors - pregnane X receptor (PXR) 
and constitutive androstane receptor (CAR) and transcription factor aryl hydrocarbon receptor 
(AhR). 
 This doctoral thesis presents the results of three studies dealing with the gene 
regulation of drug metabolizing enzymes and drug transporters via nuclear receptors. 
 In the first part of this thesis we examined whether warfarin enantiomers 
stereoselectively interact with PXR to up-regulate main drug metabolizing enzymes of the 
cytochrome P450 superfamily. Warfarin, a widely used anticoagulant, is administered as 
racemic mixture of R- and S-warfarin. S-warfarin has five times greater anticoagulant potency 
than R-warfarin. We found that R-warfarin interacts with PXR and transactivates CYP3A4 and 
CYP2B6 mRNA in primary human hepatocytes and LS174T intestinal tumor derived cell line. 
S-warfarin showed lower potency to transactivate target genes via PXR. Furthermore, we 
found that 4´- and 10-hydroxywarfarines are potent ligands of PXR and inducers of CYP3A4 
and CYP2C9 mRNA in primary human hepatocytes and therefore 4´- and 10-
hydroxymetabolites of R-warfarin may be also ligands of PXR. These results raise the 
consideration whether the use of S-warfarin together with VKORC1 and CYP2C9 genotyping 
would be safer alternative of anticoagulant therapy in relation to drug-drug interactions than 
the current use of racemic warfarin.  
 Next part of this thesis is focused on glucocorticoid receptor regulation of organic 
cation transporter 1 (OCT1) expression via HNF4α up-regulation in primary human 
hepatocytes and hepatocarcinoma cell lines HepG2 and MZ-Hep1. We found that OCT1 is 
transactivated via HNF4α up-regulation via GR in primary human hepatocytes, but not in 
model cell lines. This discrepancy may be caused by affecting of transcription factors 
involved in regulation of OCT1 due to different signaling pathways in normal hepatocytes and 
tumor derived cell lines. We did not found any GR response element (GRE) within 1,7 kb 
OCT1 promoter sequence and therefore OCT1 is unlikely  transactivated via GR.  
The last part of this thesis is focused on finding of novel CAR ligands among newly 
synthetized quinazoline derivates. We have tested 20 compouds, three of them, namely CHP4, 
CHP5 and CHP6, were found to interact with ligand binding domain of CAR. We showed, 
that CHP4, CHP5 and CHP6 transactivate pBREM/2B6 promoter via both CAR1 and CAR3 
splice variants in the COS-1 cell line. CAR3 exhibits affinity to direct activators. CHP4, 
CHP5 and CHP6 significantly enhanced the interaction between C- and N-region of CAR 
LBD showing these compouds are direct CAR activators. Finally, CHP4, CHP5 and CHP6 
up-regulated CAR target gene CYP2B6 mRNA in primary human hepatocytes and HepG2 
cell line. New model CAR ligands might help us to elucidate physiologic functions and the 
role of this receptor in organism. 
